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1. Introduction 
The different organs in human organism are constituted by tissues with mature and 
specialized cells and its specific stem cells. Stem cells represent only a minuscule fraction of 
cells that constitute each tissue but they are the only cells with self-renewal capacity. The 
organ-specific stem cells have specific properties that maintain tissue integrity and are 
defined mainly by their capacity to undergo self-renewal, as well as differentiation into 
mature cell types that comprise each organ (Shipitsin & Polyak, 2008).  
The malignant neoplasias are believed to result from sequential mutations that can occur as 
a consequence of progressive genetic instability and/or environmental factors. An accordant 
observation in several investigations has been the association between deregulation of stem 
cells and carcinogenesis, because there are regulatory mechanisms of self-renewal in normal 
stem cells that also frequently regulate oncogenesis. In consequence, experimental and 
clinical evidences that have recently been accumulated support the hypothesis that cancer 
may arise from mutations in normal stem cell populations, and that these cells would be 
subject to ongoing genetic and epigenetic changes that could help to establish the disease. 
The cancer stem cell (CSC) hypothesis states that normal stem cells may be the cells of 
cancer origin, and that a specific subset of cancer cells with stem cell characteristics can give 
rise to a hierarchy of proliferative and progressively differentiated bulk of tumoral cells, 
leading to tumor initiation, progression, and recurrence. In fact, there are several 
investigations that recently have identified specific CSC markers showing similar expression 
profiles than the normal stem cells of same organ. Moreover, CSCs can be prospectively 
isolated based on expression of a specific molecule or combination of molecules, and have 
the ability to give rise to new tumors when xenografted in immunodeficient mice. 
Additional confirmations that stem cells can play a role in carcinogenesis are the homologies 
found between normal adult stem cells and cancer cells. Besides self-renewal capacity, these 
characteristics include the production of differentiated cells, activation of antiapoptotic 
pathways, induction of angiogenesis, resistance to apoptosis and drugs (due to active 
telomerase expression and elevated membrane transporter activity), and the ability to 
migrate and propagate (Wicha et al., 2006). Notwithstanding, different from normal adult 
stem cells that remain constant in number, CSCs can increase as the tumors grow, and 
originate the progeny that can be both locally invasive and/or colonize distant sites.   
Therefore, the consolidation of CSCs knowledge into our current view of multistep cancer 
development has important implications for defining the target population for therapeutical 
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approach and for understanding specific events required for realization of malignant 
potential, and the advances in CSC knowledge can help to build further evidences for 
potential targeting pathways in treatment of several cancer types. 
2. Stem cells 
Despite wide variety of cells that can be identified in adult tissues, all cells derive from a 
single egg cell after fertilisation of an ovule by a spermatozoid. Egg fertilisation results in 
creation of totipotent stem cells, which are the precursor cells of all tissues of embryo, yolk 
sac, amniotic sac, allantois, and embryonic portion of placenta – chorion and others 
placental membranes. Approximately four days after fertilisation, these totipotent stem cells 
undergo several mitotic divisions to form identical cells, and after this point, they tend to 
lose their high proliferative potential and begin to specialise by becoming pluripotent stem 
cells, which then can generate most of tissues necessary for embryo formation. 
Subsequently, the pluripotent stem cells begin to divide, and they mature into more 
specialised stem cells – the progenitor cells. These progenitor cells are called multipotent 
stem cells. They are committed to generate specific cell groups that have distinct functions, 
such as haematopoietic stem cells, which produce erythrocytes, white blood cells and 
platelets. Furthermore, multipotent stem cells become more specialised and give rise to 
precursor committed cells or unipotent stem cells, which are able to differentiate into only 
one cell lineage. 
The unipotent stem cells’ function is to act as cell reservoirs for different tissues. Certain 
unipotent cells, such as adult hepatocytes, may even have long-term repopulating functions. 
Finally, from unipotent stem cells originates the nullipotent cells that are terminally 
differentiated and have lost their self-renewal capabilities. Therefore, stem cells show 
diverse degrees of plasticity or differentiation potential and can be defined as units of 
biological organisation that are clonal precursors of more identical stem cells; in addition, 
they  can produce a defined set of differentiated and specialised progeny (De Miguel et al., 
2009; He et al., 2009; Slack, 2008) (Figure 1). 
 
 
 Totipotent         Pluripotent        Multipotent         Unipotent         Nullipotent 
Fig. 1. Stem cells plasticity. Stem cells show diverse degrees of differentiation potential 
The integrity of adult tissues is maintained by the continuous replacement of cells that 
regularly differentiate and die. Thus, in most adult tissues, there are pools of progenitor 
cells that are able to multiply and differentiate into specialised tissue of origin, while at the 
same time, they are able to maintain a reserve of undifferentiated cells. These adult 
progenitor cells are defined as adult tissue-specific stem cells or somatic stem cells. 
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The liver is probably the best example of a tissue with stem cells and differentiated cells 
because it has a remarkable regeneration capacity. Centuries ago, Greek mythology 
described liver regeneration through story of Prometheus, the mortal who stole the secret of 
fire from Zeus and introduced it to humans. Prometheus was then punished by having his 
liver plucked out by an eagle daily. His liver regenerated overnight, thus providing the 
eagle with eternal food and Prometheus with eternal torture. This phenomenon was later 
recognised in medicine, albeit at a slow rate, and it was probably first introduced into 
scientific literature in the 1800s in several German reports (Ankoma-Sey, 1999). 
In modern times, the next significant scientific advance in elucidation of liver regeneration 
was introduced by Higgins & Anderson in 1931. They demonstrated experimentally that 
surgical removal of two-thirds of the rat liver (partial hepatectomy) was possible and that it 
resulted in regeneration of remaining lobes of liver by compensatory hyperplasia. The 
whole process lasted five to seven days (Higgins & Anderson, 1931). 
During the 1960s, first genetic evidence of stem cells existence was detailed. The authors of 
these studies demonstrated that bone marrow contains a unique specific type of cell that 
could give rise to myeloerythroid colonies in spleen. In these experiments, genetically 
marked cells (random DNA breaks and translocations) were generated by sublethal 
irradiation of the donor bone marrow. These cells could self-renew and differentiate in 
spleens of conditioned transplanted host mice, indicating that the genetically marked stem 
cells were able to reconstitute and radioprotect mice after sublethal irradiation (Becker et al., 
1963; Becker et al., 1965). 
In summary, stem cells differ from other cells in the body because they have four major 
properties: a) they are undifferentiated and unspecialised; b) they are able to multiply for 
long periods while remaining undifferentiated (generally slowly cycling), such that a small 
number can create a large population of similar cells; c) they are capable of differentiating 
into specialised cells of a particular tissue (produce progeny in at least two lineages); and d) 
they can be serially transplanted. The combination of these properties is often referred to as 
“stemness” (Mikkers & Frisen, 2005).  
Stem cells can divide symmetrically or asymmetrically. A symmetrical division occurs when 
two daughter cells share the same stem cell features, and it occurs when their numbers 
(stem cell pool) need to be expanded, such as during embryonic development or after tissue 
injury. An asymmetrical division occurs when one of the progeny remains undifferentiated, 
thereby replenishing the pool of stem cells, while the other daughter cell can proliferate and 
differentiate into specialised cells to generate new tissue mass (Figure 2). 
2.1 Pluripotent stem cells 
During embryonic development, the embryo originates from a single fertilised egg, also 
called a zygote, and it divides into extraembryonic (trophoblasts) and embryonic 
components (Gardner, 1983). The embryonic component is located inside the embryo. It 
refers to the inner cell mass of blastocysts, and is the originator of all tissues of embryo, 
foetus and adult organism (Brook & Gardner, 1997; Evans & Kaufman, 1981). The inner cell 
mass is also the source of embryonic stem (ES) cells and has the ability to give rise to all 
three embryonic germ layers: ectoderm (epidermal tissues and nervous system), endoderm 
(interior stomach lining, gastrointestinal tract, lungs), and mesoderm (muscle, bone, blood, 
urogenital) (Li & Xie, 2005; Thomson et al., 1998). 
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Fig. 2. Self-renewal is the fundamental characteristic of stem cells. Stem cell can be induced 
to undergo symmetric division when necessary and stem cells also are able to divide 
asymmetrically, originating one undifferentiated cell, which restores the stem cell pool, and 
another cell committed to differentiation 
 
 
 
Fig. 3. The totipotent zygote is formed after fertilisation of an ovule by a spermatozoid and 
undergoes several mitotic divisions to form blastocyst, which is divided into extraembryonic 
(trophoblasts) and embryonic components (inner cell mass), from which all tissues of adult 
organism originate. Pluripotent stem cells can be isolated from inner cell mass or gonadal 
buds of embryo using a feeder layer of foetal fibroblasts, and these cells can be differentiated 
into cells of every lineage in human body. Stem cells restricted to one lineage (ectoderm, 
mesoderm or endoderm) are called multipotent stem cells 
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As development proceeds, the need for organogenesis arises, and over five-nine weeks post-
fertilisation, the embryo proper forms germline stem cells for reproduction and somatic 
stem cells for organogenesis. Germline stem cells derive from gonadal buds of the embryo 
and are an alternative source of ES cells (Liu et al., 2004). The ES cells of the inner cell mass 
or the gonads are considered to be pluripotent due their ability to differentiate into cells of 
every lineage in the body (Anderson et al., 2001). Moreover, ES cells can undergo cell 
divisions without differentiation through symmetrical divisions (Fuchs & Segre, 2000) 
(Figure 3). 
Interestingly, the term “ES cells” was introduced to distinguish pluripotent embryonic stem 
cells from teratocarcinoma-derived pluripotent embryonic carcinoma (EC) cells (Martin, 
1981). Teratocarcinomas are malignant, multidifferentiated tumours containing a significant 
population of undifferentiated cells. These tumours were first described in 1970 when 
researchers reported that early mouse embryos grafted into adult mice produced 
teratocarcinomas (Solter et al., 1970; Stevens, 1970). In humans, teratocarcinomas are formed 
from a malignant form of primordial germ cells and usually occur in ovaries and testes. The 
EC cells proliferate extensively in vitro and remained undifferentiated even at high densities, 
and unlike ES cells and germline stem cells, they contain chromosomal alterations. Another 
characteristic of EC cells is that they have a more limited differentiation potential than ES 
cells in vitro and in vivo (Andrews, 1998). 
The first isolated ES cells were obtained from mouse blastocysts in 1981 (Evans & Kaufman, 
1981; Martin, 1981). After 17 years, James Thomson's team described the first human ES cells 
that were isolated (using a similar protocol as for mice) from fresh or frozen embryos 
obtained through in vitro fertilisation for reproductive purposes, which were donated by 
parents (Thomson et al., 1998). In same year, Shamblott & colleagues isolated pluripotent 
cells from human embryonic and foetal gonads. Since then, it has been possible to obtain 
several immortal ES cell lines from mice and humans using feeder layers of mouse foetal 
fibroblasts in presence of leukaemia inhibitory factor (LIF). These immortal cell lines present 
the same in vivo properties in vitro and grow indefinitely in laboratories under specific 
conditions. However, differences between mouse ES cells and human ES cells have been 
found, and subsequently, several lines of human ES cells has been described and added to a 
record that can be found on homepage http://stemcells.nih.gov/research/registry. 
The criteria used to define cell lines as ES cells are the following: a) must be derived from 
pre-implantation embryos, b) must have prolonged proliferation in undifferentiated state, 
and c) must be able to differentiate into cells of the three germ layers, even after prolonged 
culture. In this manner, some investigators observed that ES cell lines subcutaneously 
injected into SCID mice could give rise to distinct tissues, such as neural epithelium 
(ectoderm); cartilage, bone and smooth/striated muscle (mesoderm); and gut (endoderm) 
tissues (Pera et al., 2000; International Stem Cell Initiative, 2007). 
Human ES cells can grow as colonies, and they express certain undifferentiated stem cell 
markers, such as transcription factors Oct-4 (octamer-binding protein 4), Sox-2 and Nanog, 
as well as cell surface proteins SSEA (Stage Specific Embryonic Antigen)-3, SSEA-4, TRA 
(Tumour Rejection Antigen)-1-60, TRA-1-80 and alkaline phosphatase (Miguel et al., 2010). 
These cells have normal and stable karyotypes during continuous passaging and can be kept 
in their undifferentiated state for multiple cell divisions when cultured under specific 
conditions in vitro (Shamblott et al., 1998; Shamblott et al., 2001; Amit et al., 2000). On the 
other hand, when grown in conditioned media, ES cell lines can be induced to differentiate 
in tissue-specific manners or into several other tissues (embryoid bodies), which simulates 
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the development of a pre-implanted embryo. Moreover, human ES cell lines have been used 
to generate cells of different lineages, including neurons, cardiomyocytes, blood 
progenitors, hepatocytes, retinal precursors and ǃ-cells of pancreatic islets (Cowan et al., 
2004). 
These remarkable characteristics of human ES cells have generated great interest among 
researchers around the world, and studies of ES cell lines have been conducted to elucidate 
the molecular mechanisms involved in totipotency and pluripotency of stem cells, as well as 
to develop methodologies of ES cell differentiation into different tissues. Future 
manipulation of these pathways involved in cell potency may serve as the basis for 
modification of adult tissue-specific stem cells into less differentiated cells, thereby 
increasing their ability to differentiate and proliferate. Furthermore, pluripotent stem cell 
lines could allow for the testing of new medications in several cell types, thereby aiding the 
advancement of drug development process. As a result, only drugs that are both safe and 
have beneficial effects in various tests on these cell lines will be forwarded to animal 
experimentation and human trials. 
The most fascinating development in history of ES biology is the generation of ES-like cells, 
called “induced pluripotent stem (iPS) cells”, that do not involve destruction of human 
embryos. The destruction of embryos has caused huge religious and ethical problems and 
significant public unease. Several countries (e.g., Austria, Germany, Italy, and Brazil) have 
introduced legislation prohibiting human embryo research. However, in 2006, Takahashi 
and Yamanaka demonstrated that retroviral-mediated overexpression of a set of only four 
pluripotent genes, Oct4, Sox2, c-Myc and Klf4 (Kruppel-like factor 4), was sufficient to 
reprogram murine fibroblasts to ES-like cells. The first iPS cells generated were from mice, 
but within months, the same group described the generation of human iPS cells (Takahashi 
et al., 2007; Yu et al., 2007). 
2.2 Adult tissue-specific stem cells 
Adult tissue-specific stem cells are indispensable components of tissue homeostasis because 
they support ongoing tissue regeneration by replacing cells that are lost due to natural cell 
death (apoptosis) or injury (Spradling et al., 2001). These cells are undifferentiated but are 
found in adult differentiated tissues, and most of them have self-renewal capacity 
throughout the entire lifetime of an organism; in addition, they can give rise to other adult 
tissue-specific stem cells and precursor cells that can produce mature differentiated cells by 
asymmetric division (Weissman et al., 2001). 
Adult tissue-specific stem cells represent a small percentage of total cellularity. Previous 
studies have reported many kinds of adult tissue-specific stem cells, and their experimental 
assays have revealed different characteristics of stem cell behaviour. Adult bone marrow, 
for example, contains at least three distinct types of adult multipotent stem cells: 
haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and endothelial 
progenitor cells (EPCs). The HSCs are quite rare, with a frequency about of 1 in 10,000 of all 
bone marrow cells, and the selection of human HSCs is based on combined expression of 
CD34 and aldehyde dehydrogenase (ALDH) (Mirabelli et al., 2008). The MSCs are also 
scarce in human bone marrow aspirates (1-20 in 10.000), and they decrease in quantity with 
age. Human MSCs express a wide range of markers, such as CD105, CD73, CD90, CD29, 
HLA class-I, CD44, CD49e, CD34, CD31, CD14, CD19, and HLA class II. In vitro, MSCs 
adhere to plastic surfaces and can differentiate into bone, cartilage or fat. Finally, bone 
marrow-derived EPCs are a unique population of blood mononuclear cells that have a role 
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in postnatal neovascularisation during wound healing and tumour development. The 
identification of human EPCs relies on expression of VEGFR2, c-kit, or CD34.  
In small intestine, there is estimated to be around 10 stem cells near the bottom of the crypt 
out of a total crypt population of less than 300 cells. Small intestinal stem cells are 
multipotent and can generating Paneth cells, mucin-producing goblet cells, columnar 
enterocytes and enteroendocrine cells (all four lineages) (Sancho et al., 2004). In skeletal 
muscle, satellite stem cells are unipotent and the major source of myogenic cells for growth 
and repair, and they comprise around 5% of adult muscle nuclei present within muscle 
fibres. The stem cell markers of these cells include M-cadherin and transcription factor Pax-7 
(Goldring et al., 2002). 
Kidney stem cells compose 0.8% of all cortical cells and have been isolated from the cortical 
interstitium. They have been shown to express Pax-2, CD133, and classical mesenchymal 
markers such as CD73, CD29, and CD44. In vitro, these cells have been shown to 
differentiate into epithelial and endothelial cells (Gupta & Rosenberg, 2008). In mammary 
glands, stem cells are bipotent, generating luminal and myoepithelial cells, and they can be 
identified from terminal ductal lobulo-alveolar units by expression of CD44, CK19, or 
epithelial surface antigen-positive (ESA) or by negative expression of common acute 
lymphoblastic leukaemia antigen (CALLA-) (Clarke et al., 2003). In the skin, epithelial stem 
cells are multipotent and give rise to epidermal progenitors for tissue repair and also hair 
matrix progenitors, which generate the hair shaft. These stem cells can be identified by 
CD34 and ǂ6 integrin expression (Blanpain et al., 2004). 
In summary, there are two criteria to define functional adult tissue-specific stem cells: self-
renewal capacity and multipotentiality, which is most important when investigating new 
adult tissue-specific stem cells populations. However, there are controversies regarding the 
identity and functional potency of stem cells in some organs, such as in lung and pancreas. 
Kim & colleagues (2005) identified bronchoalveolar stem cells, but in 2009, Rawlins & 
colleagues revealed that these stem cells do not contribute to alveoli lineages during normal 
homeostasis and regeneration. Similar controversies have been debated in endocrine 
pancreas, which is composed of islets of Langerhans formed by ǂ, ǃ, δ and PP cells. 
Although embryonic pancreatic duct stem cells have the plasticity to give rise to endocrine 
and exocrine lineages, adult pancreatic duct stem cells generate acinar cells (exocrine 
pancreas) but not insulin-producing ǃ-cells (Solar et al., 2009). Therefore, the distinction 
between adult tissue-specific stem cells characteristics, as well as their true potential, 
remains unclear. Thus, these facts should lead to future investigations aiming to clarify 
whether there are other common features among adult tissue-specific stem cells and to 
define the true roles of these cells that possess a wide in vivo differentiation potential. 
2.3 Stem cell niches 
Stem cells reside in a special microenvironment termed a “niche,” which varies in nature 
and location depending on tissue type. The concept of niche was first proposed by Schofield 
(1978) to describe how bone marrow-derived haematopoietic stem cells, while in 
proliferative state, had increased proliferative potential when compared to haematopoietic 
cells that reside in spleen (spleen colony-forming cells, CFU-S). Historically, the term niche 
is typically used to identify the location of stem cells. Currently, the definition of niche is 
broader and includes the cellular components of microenvironment surrounding the stem 
cells, in addition to the signals that are emitted by these stromal support cells in vivo. 
Furthermore, the stem cell niche can be defined as a group of cells in a specific tissue whose 
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aim is the maintenance of adult tissue-specific stem cell pool (Spradling et al., 2001). 
Therefore, the niche provides a mechanism to precisely balance the production of stem cells 
and progenitor cells to maintain tissue homeostasis. 
Although there are specific niches for each stem cell type and these special 
microenvironments appear to be structurally and functionally diverse, it is possible to find 
common features among them. The pioneering system used to study HSCs is the bone 
marrow, and currently, the HSC niche is conceptually divided into three parts: osteoblastic 
zone, vascular zone, and zone neighbouring haematopoietic stem cells. Another example is 
the neural stem cell niche, which supports neurogenesis in the adult brain and can be found 
in both subventricular zone (SVZ) and subgranular zone (SGZ) of hippocampal region. In 
these zones, the endothelial cells that form blood vessels and the specialised basal lamina 
are essential cellular components of neural stem cell niche (Doetsch, 2003). 
The niche functions as a physical anchor for stem cells by generating factors that control 
stem cell proliferation and fate. Calvi & colleagues (2003) demonstrated in bone marrow that 
osteoblastic cells located in lining of endosteal surface express N-cadherin and physically 
attach HSCs, thereby acting as a regulatory component with capacity to control the HSCs 
number. In general, other mediating adhesion molecules can anchor cells to extracellular 
matrixes; for example, integrins, certain types of collagen (I-V), cadherins, and ǃ-catenin 
play an important role in stem cell/microenvironment interaction (Simmons, 1997). With 
regard to the brain, it is known that endothelial cells can attach to astrocytes, which have 
stem cell features and give rise to neuroblasts in the SVZ and SGZ, thereby producing 
signals that control the stem cell population (Doetsch, 2003). 
Inside the niche, stem cells are often in the quiescent state in terms of cell cycle. This 
quiescent state is vital for ensuring maintenance of tissues throughout life and prevents 
premature extinction of the stem cell pool caused by numerous conditions of stress 
experienced by cells. Niches for quiescent stem cells are located in hypoxic tissue regions 
that are poor in vasculature. For example, in the bone marrow, quiescent HSCs are 
maintained in osteoblastic niche (hypoxic niche), while the HSCs and haematopoietic 
progenitors in highly proliferative state are found in vascular niche (oxygenic niche) (Yin & 
Li, 2006; Jang & Sharkis, 2007). In response to injury, a microenvironmental change in tissue 
might actively signal to the niche to mobilise quiescent cells, which would induce the 
proliferation and transition of stem cells to the vascular niche area. Furthermore, after 
irradiation treatment, surviving HSCs must enter the proliferative stage to produce 
progenitor cells that will give rise to differentiated cells. Nonetheless, HSCs tend to exit of 
the cell cycle once the haematopoietic cells have been compensated (Suda et al., 2005). 
Signalling pathways and molecular mechanisms can control stem cell fate decisions through 
a delicate balance between regulatory factors. To ensure appropriate control of cellular 
behaviour, the intrinsic stem cell factors must be subjected to microenvironmental 
regulation or extrinsic factors provided by niche. Therefore, both intrinsic and extrinsic 
factors are required to maintain stem cell properties and to direct stem cell self-renewal and 
differentiation. Several signalling molecules have been shown to be involved in maintenance 
of stem cell niche. For example, the Wingless-related protein (Wnt) signalling pathway is 
important for stem cell self-renewal, but expression of Wnt pathway inhibitors, such as axin, 
leads to inhibition of stem cell proliferation (Nusse, 2008). Studies using gene targeting have 
demonstrated that the bone morphogenetic protein (BMP) signalling pathway has an 
important role in the suppression of Wnt signalling pathway, thereby providing balanced 
control between stem cell activation and self-renewal. Homeobox genes induced by Wnt 
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activity, such as HoxB4 and Notch, can also participate in the process of stem cell expansion. 
The Notch pathway is important for maintaining stem cells in an undifferentiated state. 
Signals mediated by transformation growth factor beta (TGF-ǃ) and family members, 
including BMPs, Nodal and activins, have been implicated in the maintenance and 
differentiation of various types of adult tissue-specific stem cells (Watabe et al., 2008). In 
short, there are several growth factors that operate at different stages in the stem cell 
lineages, indicating the need for strict control over cell division within the stem cell niche. 
For maintenance of an adequate number of stem cells within their niches and meeting the 
demand of differentiated cells within the surrounding tissue, it is essential that there be a 
strict regulation of balance between symmetric and asymmetric stem cell divisions. The 
niche contributes to orientation of asymmetric division, with the aim of controlling the flow 
and direction of committed progeny. As a result, one daughter cell is destined to become a 
stem cell, stays in stem cell niche, retains its self-renewal properties and receives inhibitory 
differentiation factors. In contrast, the other daughter cell leaves the niche to become 
committed to proliferate and differentiate along a determinate lineage (progeny cell), and it 
can receive differentiation signals that can overcome this state to eventually become a 
functionally mature cell.  
In general, both embryonic and adult stem cells must have the capacity to grow and 
differentiate in response to signals emitted by their specific niche. To sustain these functions 
throughout the organism’s life span, there are essential mechanisms that control adult 
tissue-specific stem cells and the nature of a possible tumour transformation (Iwasaki & 
Suda, 2009). 
3. Stem cells and cancer 
3.1 Brief historical review of stem cells and cancer 
The resemblance between stem cells and cancer cells was observed a long time ago. The first 
study concerning hypothesis of cancer origin from a rare population of normal cells with 
stem cell properties was proposed almost 150 years ago (Durante, 1874; Wicha et al., 2006). 
At that time, Cohnheim (1875) also proposed the hypothesis that stem cells could be 
misplaced during embryonic development and become the source of tumours that would be 
formed later in life. 
This subject was revived over 40 years ago when a several investigators confirmed the CSC 
hypothesis by demonstrating that a single tumour cell could generate heterogeneous 
progeny and give rise to a new tumour through studies performed in tumours derived from 
ascites fluid in rats and teratocarcinomas and leukaemias in mice (Bruce & Van Der Gaag, 
1963; Kleinsmith & Pierce, 1964; Makino, 1956). In this vein, Park et al. (1971) observed 
certain myeloma tumour stem cells in mice using a primary cell culture assay, and 
Hamburger and Salmon (1977) corroborated the hypothesis that some cancers contain a 
small subpopulation of cells that are similar to normal stem cells. They observed in primary 
bioassays that the expansive growth of malignant lesions suggests the presence of a CSC 
population with stem cell properties, including indefinite proliferation.  
In animal models, the ability of a small population of cells to originate a new malignant 
neoplasia was demonstrated in a classic experiment utilising transplantation of cells from 
human acute myeloid leukaemia (AML) that expressed certain cell surface markers 
associated with normal haematopoietic stem cells (Lapidot et al., 1994). The authors showed 
that these transplanted cells could initiate leukaemia in non-obese diabetic/severe combined 
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immunodeficient (NOD/SCID) mice, while other isolated cells could not. Since then, this 
assay has become the standard method for determining whether cell populations isolated 
from solid tumours are CSCs. 
Based on ability of diverse purified populations to form leukaemia in NOD/SCID mice, 
various studies embarked on a search for stem-like cells in leukaemias. Bonnet and Dick 
(1997) recognised in AML that the injection of a small subset of leukaemic cells with a 
primitive haematopoietic progenitor phenotype (CD34+CD38-) resulted in leukaemias that 
could be serially transplanted into secondary recipients, and they also observed their ability 
to perpetually self-renew. Since then, putative CSCs have been isolated from many other 
tumour types, including brain, breast, colon, pancreas, prostate, lung, and head and neck 
cancer (Collins et al., 2005; Dalerba et al., 2007; Kim et al., 2005; Li et al., 2007; Prince et al., 
2007). 
3.2 Cancer stem cell hypothesis 
The research fields of cancer and stem cell biology share common features regarding cellular 
proliferation properties. In humans, normal adult multipotent stem cells are usually self-
renewing. This self-renewal ability allows stem cells to produce at least one progeny cell 
with a similar developmental capacity, and available current lines of evidence indicate that 
this cell population, through initial genetic or epigenetic alterations, can become the cells 
responsible for the development of several tumours through a progressive establishment of 
a CSC population.  
It is widely accepted that genetic instability drives malignant transformation. The stem cell 
origin of cancer hypothesis considers that stem cells or other differentiated cells that have 
acquired self-renewal ability tend to accumulate genetic alterations and evade the strict 
control of their microenvironment, thereby giving rise to tumoural evolution (Shipitsin & 
Polyak, 2008). Thus, the CSC model suggests that tumour progression, metastasis and 
recurrence after therapy can be driven by a rare subgroup of tumoural cells that have the 
capacity to self-renew, while the bulk of the tumour does not have this capacity. Therefore, 
the deregulation of this self-renewal process leading to stem cell expansion may be a key 
event in carcinogenesis, and while self-renewal can drive tumorigenesis, the differentiation 
process may contribute to tumour phenotypic heterogeneity (Kakarala & Wicha, 2008; Shay 
& Wright, 2010).  
Normal adult stem cells have relatively long telomeres compared to more differentiated 
somatic cells, they are usually quiescent or proliferate more slowly than their differentiated 
progeny, and they have increased longevity; for this reason, they are exposed to more 
damaging agents than more differentiated cells over time. Thus, they accumulate mutations 
that are then transmitted to the rapidly proliferating progeny (Dontu et al., 2003). Mutations 
in the DNA of normal adult stem cells appear to be the initiating events in several types of 
malignant tumours, and some of the strongest evidence supporting this hypothesis is that a 
specific group of cells can be prospectively isolated based on their peculiar features; later, 
these cells can be serially transplanted into immunodeficient mice (Alison et al., 2010). 
If normal adult stem cells are the founding cells of several cancer types, then CSCs probably 
inherit many of their characteristics. The CSCs are a population of cells that are more 
tumourigenic than the bulk tumour population and can be defined mainly through the 
expression of unique properties, such as specific detoxification enzyme systems, molecular 
surface markers, and embryonic signalling pathways (Alison et al., 2010). The main 
hallmarks of CSCs are their properties of self-renewal, their ability to generate tumours from 
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very few cells, their slow cell division rate, their ability to give rise to phenotypically diverse 
progeny, and their selective resistance to radio- and chemotherapy (Reya et al., 2001).  
The self-renewal and differentiation characteristics of CSCs lead to the production of all cell 
types in a tumour, thereby generating wide heterogeneity (Campbell & Polyak, 2007). The 
differentiated cells constitute the bulk of the tumour but are not usually tumourigenic due 
to their lack of self-renewal capacity and limited proliferation potential (Ginestier et al., 
2007). However, it has been shown that the switch to carcinogenesis can occur in either the 
stem cells or their differentiated progeny, which sometime acquire the ability to self-renew 
(Dontu et al., 2003). In several tissue systems, it has been proposed that certain committed 
progenitor cells might become CSCs through a dedifferentiation process, which would occur 
by acquisition of stem cell properties (Cobaleda et al., 2007). 
Further evidence indicates that stem cells can play a role in carcinogenesis. A previous study 
showed that there are similarities seen between normal stem cells and cancer cells. In 
addition to self-renewal capacity, these characteristics include activation of anti-apoptotic 
genes, production of more differentiated cells, induction of angiogenesis, resistance to 
conventional radio- and chemotherapy (e.g., due to active telomerase expression, high 
ALDH expression, elevated membrane transporter activity), and ability to migrate and 
disseminate in metastasis (Wicha et al., 2006). 
Conversely, there are some important differences between these two types of cells, which 
also corroborates the CSC hypothesis. While normal stem cells are chromosomally stable 
and contain a normal diploid genome, cancer cells have a significant number of 
chromosomal rearrangements and are almost always characterised by aneuploidy. 
Moreover, cancer cells may lack cell cycle checkpoint activity that allows them to completely 
growth arrest. More importantly, a major difference that has been found between normal 
adult tissue stem cells and cancer cells is that stable telomere length is maintained in 
malignant cells (Shay & Wright, 2010).   
Notwithstanding the evidence that has been found, the extensive characterisation of murine 
CSC models has not yet resulted in the identification of their human counterparts for all 
tumour types. More than one CSC type with a different phenotype per tumour type could 
be likely, which makes the search for a definitive cancer stem cell hypothesis even more 
difficult. 
3.3 Isolation and purification of CSCs 
Although the concept that cancers arise from stem cells was first proposed more than 150 
years ago, it is only recently that advances in stem cell biology have allowed for more direct 
testing and validation of the CSC hypothesis. It is well settled that CSCs share some 
properties expressed by normal stem cells. Current methods for determining whether cell 
populations isolated from solid tumours are CSCs consist of purification of these cells from 
tumour samples based on the properties of normal stem cells, such as expression of specific 
cell surface markers of stemness (Al-Hajj et al., 2003), their ability to form spheres in culture 
(Dontu et al., 2003), membrane efflux activity through drug-efflux pumps (Goodell, 2002), 
and enzymatic activity detection of cytoprotective enzymes as aldehyde dehydrogenase 1 
(ALDH1) (Nagano et al., 2007). Additionally, purified cells are then tested for the capacity to 
originate tumours when injected into immunodeficient mice. 
The tumour initiation aspect of CSCs refers to the ability of these cells (at a reduced number) 
to originate malignant tumours in immunocompromised mices. The expression of some 
specific cell surface markers has been investigated to facilitate the identification and 
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purification of CSCs, and there are currently several stem cell markers that are shared by 
CSCs in multiple human tumour types, but this issue is best addressed in the next section of 
this chapter. 
Hoechst 33342 membrane efflux activity is a discriminating characteristic of quiescent stem 
cells that is lost when these cells enter in cycle, and this activity allows the identification 
through flow cytometric analysis of a small stem-like cell population designated as a side 
population (SP). In fact, it has been hypothesised that the main characteristic of the SP is a 
universal stem cell phenotype (Zhou et al., 2001). Although heterogeneous, SP cells are 
observed in primitive retinal and cardiac cells (Bhattacharya et al., 2003; Hierlihy et al., 
2002); in epidermal, neural, mammary, and haematopoietic stem cells; and also in certain 
embryonic stem cells (Zhou et al., 2001). 
The SP cells are also associated with resistance to toxins and drugs, and this characteristic is 
a result of increased expression of membrane transporter proteins (ABC drug transporters), 
such as P-glycoproteins or BCRPs (breast cancer resistance proteins). In addition to acting as 
functional regulators of stem cells, they contribute to the defence against damaging agents 
through the elimination of xenobiotic toxins (Zhou et al., 2001). Thus, tumours might have a 
population of drug-resistant pluripotent cells that can survive chemo- and radiotherapy and 
subsequently repopulate the tumour (Charafe-Jauffret et al., 2008). 
The ALDH gene superfamily encodes a family of NAD(P)+-dependent metabolic enzymes 
that are involved in detoxifying a wide variety of aldehydes to their corresponding weak 
carboxylic acids. ALDH activity, as a CSC specific marker, was discovered recently after 
great investigation, especially of haematological and breast malignancies (Charafe-Jauffret et 
al., 2009; Ginestier et al., 2007), although it has also been implicated as a CSC marker in 
several others tumour types (Ma et al., 2008). In human breast cancer cell lines, high ALDH 
activity has been used successfully to select CSCs (Charafe-Jauffret et al., 2009).     
In vivo tumourigenic xenotransplantation assays performed in immunodeficient mice 
(NOD/SCID) are currently the gold standard for successful CSC isolation and purification 
These mice have a lack of major elements of the immune system, and therefore, they do not 
reject human cells. Because a large amount of human tumour cells must be 
xenotransplanted into immunodeficient mice to originate tumours, it was initially thought 
that CSCs were infrequent in tumours. However, this might be because the human cells in 
this assay are in a foreign microenvironment, as transplantation of mouse tumour cells into 
other mice indicates that CSCs can be quite common in some determined cancers. This in 
vivo assay is frequently supplemented by a clonogenicity assay that assesses the ability of 
the cells to form spheres and determines the frequency of which these isolated cells can form 
colonies (neurospheres, mammospheres, or colonospheres) when they are plated at a low 
density under non-adherent conditions in semi-liquid medium. This technique is based on 
the unique property of stem cells to survive and grow in serum-free suspensions, while 
differentiated cells undergo anoikis and die under these conditions. The resulting spheres of 
cells can be then serially passaged for experiments, originating secondary and tertiary 
spheres with a cellular composition resembling that of primary spheres and proving their 
self-renewal capacity (Alison et al., 2011). 
Therefore, the standard procedures for the isolation of CSCs have been similar in several 
investigations. Among the most used in vivo models is tumour cell fractionation according 
to cell-surface markers with stem cell characteristics, which is followed by a clonogenicity 
assay to verify the sphere formation capacity and their implantation into NOD-SCID mice to 
assess xenograft growth and cellular composition (Shipitsin & Polyak, 2008). 
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3.4 CSCs markers in human tumours 
CSCs have been prospectively isolated on the basis of the expression of specific surface 
molecular markers, and recent interest in CSCs arose from experiments suggesting that cells 
with stem-like properties can be sorted from solid tumours based on the expression of these 
markers. However, there is still no apparent consensus regarding the more reliable markers 
associated with the identification of CSC phenotype in some particular solid tumours, such 
as in gastrointestinal carcinomas (Alison et al., 2010). In haematological malignancies, the 
consensus is that the CD34+CD38- phenotype can identify most of the CSCs, and the 
accumulated evidence found in other tumour types indicates that markers such as 
cytoprotective enzymes, cell-adhesion molecules, and drug-efflux pumps can be associated 
with a CSC phenotype. The main surface markers currently associated with stem cells and 
CSCs include CD133, CD44, and CD24 (Al-Hajj et al., 2003; Hermann et al., 2007; O'Brien et 
al., 2007). 
The CD133 cell surface marker, also called prominin 1 (PROM1), was discovered as a 
marker of normal haematopoietic stem cells and was later used to purify putative CSCs in 
several tumour types. In brain tumours, Singh et al. (2004) found that CD133+ cells could 
successfully grow under non-attachment conditions with neurosphere-like formations, 
whereas CD133- cells could not. According to other studies, CD133 also has been shown to 
play a role in migration and asymmetrical stem cell division (Beckmann et al., 2007). 
The CD44 marker is a transmembrane glycoprotein cell surface receptor for hyaluronic acid 
that is frequently expressed as several isoforms, and it is involved in cell adhesion, 
migration, and metastasis (Shipitsin et al., 2008). It has been used to identify putative CSCs 
in breast tumours (Shipitsin et al., 2008), as well as in other tumour types, such as prostate 
(Collins et al., 2005), pancreatic (Li et al., 2007), and head and neck carcinomas (Prince et al., 
2007). Shipitsin et al. (2007) found that CD44+ tumoural mammary cells were associated 
with more invasive, proliferative, and angiogenic tumour status, thereby predicting more 
aggressive tumoural cell behaviour. Furthermore, there was a correlation between CD44+ 
tumoural cells and decreased patient survival (Shipitsin et al., 2007). 
CD24 is a mucin-like adhesion molecule expressed by neutrophils, pre B lymphocytes and a 
large variety of solid tumours. Functionally, CD24 enhances the metastatic potential of 
malignant cells because it has been identified as a ligand of P-selectin, an adhesion receptor 
on activated endothelial cells and platelets. It also enables cancer cells to bind to platelets, 
and these tumour-platelet thrombi protect cells in the bloodstream and in turn facilitate 
tumour invasion through interactions with endothelia. Lim & Oh (2005) investigated the 
role of CD24 in various human epithelial neoplasias and demonstrated that intracytoplasmic 
CD24 expression was found to be highly associated with adenocarcinomas of the colon, 
stomach, gallbladder, and ovaries. Positive or negative CD24 expression also has been used 
in combination with other markers to identify putative CSCs in tumours, and some studies 
have defined the phenotype of pancreatic CSCs as CD24+/CD44+ (Li et al., 2007). However, 
in breast and prostate cancer, putative CSCs were found with a CD24-/CD44+ phenotype 
(Al-Hajj et al., 2003; Hurt et al., 2008). 
These investigations suggest that diverse stem cell markers can be expressed by CSCs in 
different tumours, and each tumour may express a phenotypic pattern with a specific CSC 
marker combination. The significance of these observations in most human cancers remains 
to be determined. Table 1 shows the most prevalent and specific CSC phenotypes according 
to stem cell markers in tumours from different organs. 
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STEM CELL MARKER TUMOR 
CD34/CD38 Acute myeloid leukemia 
CD44/CD24-/ALDH Breast carcinoma 
Side Population (SP) Bladder carcinoma 
CD133, CD44, EpCAM, ALDH Colorectal carcinoma 
CD133, Side Population (SP) Endometrial carcinoma 
CD133 Ewing’s sarcoma 
CD44 Gastric carcinoma 
CD44, Side Population (SP), ALDH Head and neck carcinoma 
CD133, CD44, ALDH Hepatocellular carcinoma 
CD133, Side Population (SP), ALDH Lung carcinomas (non-small cell and small cell) 
CD133 Medulloblastoma, Glioma 
CD133, CD44, CD24, ALDH, EpCAM Pancreatic carcinoma 
CD133, CD44, ALDH Prostate carcinoma 
Table 1. Cancer stem cell phenotypes according to stem cell markers expression in tumors of 
different organs. 
3.5 The CSC niche 
Tumours in general have a hierarchical organisation that can be dynamically regulated by 
the surrounding microenvironment. In adults, the niche prevents tumorigenesis through 
strict control of stem cell behaviour and maintenance of the balance between self-renewal 
and differentiation, as well as between quiescence and proliferation. Accordingly, intrinsic 
mutations that regulate self-renewal, including those in the Wnt, Notch and Hedgehog 
pathways, can lead to stem cells escaping from niche control. These mutations can initiate 
dysregulation of CSCs and result in tumorigenesis. Thus, a specialised microenvironment, 
consisting of cells, matrix proteins and growth factors, is thought to physically restrain stem 
cells and enable them to maintain their stemness by providing the required factors. 
The CSC hypothesis suggests that CSCs reside in a supportive niche with a poor vascular 
supply and frequently hypoxic conditions, which would result in poor drug perfusion and 
therefore contribute to an ineffective chemotherapy response (Deonarain et al., 2009). 
Furthermore, in addition to normal adult stem cells, CSCs appear to be regulated through 
molecular stimuli that are supplied from the microenvironment by neighbouring connective 
tissue cells, mainly the fibroblast-like (mesenchymal) and endothelial cells (Alison & Islam, 
2009). There is increasing evidence that disruption of epithelial homeostasis, whereby 
tumour cells acquire a mesenchymal phenotype, is necessary for cancer development. In 
colorectal cancer, for example, the promotion of Wnt signalling in CSCs requires co-
stimulation by hepatocyte growth factor (HGF) secreted by stromal fibroblasts (Vermeulen 
et al., 2010).    
It has been established that the microenvironment adjacent to blood vessels can serve as the 
main CSC niche that controls some aspects of CSC behaviour, and this microenvironment is 
also associated with the highest tumour proliferation rates (Alison & Islam, 2009). In brain 
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tumours, CSCs identified through expression of CD133 and nestin were observed to be 
concentrated in a niche close to capillaries (Calabrese et al., 2007). 
According to Charafe-Jauffret et al. (2008), genetic and epigenetic mechanisms in the 
progenitor cells, in addition to environmental influences in the niche where these cells grow, 
may contribute to the cellular heterogeneity found in the malignant neoplasms. Recently, it 
has been suggested that the microenvironment adjacent to tumours can regulate asymmetric 
versus symmetric divisions (Alison & Islam, 2009). 
3.6 The embryonic self-renewal pathways 
Different mutations associated with cancer occur in pathways that govern stem cell 
maintenance, suggesting that dysregulation of normal mechanisms of stem cell functionality 
may also be involved in carcinogenesis. Thus, the signalling pathways that regulate normal 
stem cell development and proliferation can be identical to those that promote 
carcinogenesis, possibly through initiation of CSC proliferation (Reya et al., 2001).  
The CSCs generally have or can re-acquire the self-renewal mechanisms needed for their 
maintenance, development and expansion. In this manner, the embryonic signalling 
pathways, such as Wnt, Notch, Hedgehog (Hh), Bmi-1, PTEN, and p53, are fundamental for 
normal stem cell development and organogenesis, and these same pathways are also 
involved in driving CSC activity (Takebe & Ivy, 2010). 
The Wnt pathway is clearly important for the preservation and self-renewal of stem cells. 
Wnt signalling is known to regulate cell fate decisions and influence morphology, 
proliferation, differentiation, apoptosis, migration, and stem cell self-renewal (Turashvili et 
al., 2006). Moreover, Wnt proteins can assist in maintaining stem cells in an undifferentiated 
state within their niche, and defects in the Wnt pathway have been observed in breast and 
colon cancer carcinogenesis (Olsen et al., 2004).  
In the same manner, the Hh pathway is associated with the maintenance of stem cells in 
several malignant neoplasms, including myeloid leukaemia (Zhao et al., 2009), multiple 
myeloma (Peacock et al., 2007), and colorectal cancer (Varnat et al., 2009). The Hh pathway 
is one of the main pathways that control stem cell fate, self-renewal, and maintenance. In 
human gliomas, Hh signalling represents a new therapeutic target through its essential 
control of the behaviour of glioma CSCs (Clement et al., 2007). Through the use of both in 
vitro culture systems and NOD/SCID mice, Liu et al. (2006) found that the Hh pathway, 
together with the polycomb protein Bmi-1, play important functions in regulating self-
renewal of both normal and malignant human mammary stem cells. Furthermore, in 
agreement with Byrd & Grabel (2004), Hh signalling can target endothelial stem cells 
directly or stimulate blood vessel support cells to produce vascular growth factors. 
Recently, the Notch pathway has attracted increased consideration because several Notch 
receptors and ligands are frequently overexpressed in tumours, as has been observed in 
breast and cervical cancers (Nickoloff et al., 2003). In a study performed in human breast 
cancer, the high expression of Notch intracellular domain in ductal carcinoma in situ (DCIS) 
has been shown to correlate with reduced disease-free survival time at five years after 
surgery (Farnie & Clarke, 2007). In experimental gliomas, Notch signalling activation 
appears to be dependent on nitric oxide (NO) released by endothelial cells of the 
perivascular niche, which is important for stem-like character promotion and CSC 
maintenance (Charles et al., 2010). 
Oncogenic or tumour suppressor genes, such as HER-2, PTEN and p53, have also been 
implicated in the regulation of CSC self-renewal. These genes are usually impaired in CSCs, 
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leading to uncontrolled self-renewal, which in turn can generate resistant tumours in 
relation to current therapeutic approaches. 
3.7 Targets for therapy 
Cancer progression can be viewed as an evolutionary process that generates multiple novel 
clones, each with a specific identity. If CSCs are the origins of tumours, then these are the 
cells that must be specifically eliminated for effective therapy.  
Currently, it is well known that several cancers are peculiarly resistant to conventional 
radiotherapy and chemotherapeutic drugs that typically kill the majority of cancer cells. 
These clinical responses may reflect the targeting of the bulk of non-stem cell population. 
On the other hand, there are several specific key intracellular signalling pathways 
implicated in CSC self-renewal and proliferation processes that appear to be promising 
therapeutic targets, and a wide and diverse range of advances to eliminate the CSCs in 
malignant neoplasms are becoming evident; however, although several seem promising, a 
major difficulty will be specifically targeting these cells to avoid undesirable toxicity in vivo 
(Oliveira et al., 2010). 
An ideal therapeutic strategy might be to sensitise CSCs to chemo- and radiotherapy by 
inhibiting their stemness properties and then by promoting direct cytotoxicity. Furthermore, 
as previously mentioned, the CSC population is driven by embryonic signalling pathways, 
and the targeting of these pathways could result in increased likelihood of a successful cure. 
In this vein, several drugs directed toward the inhibition of embryonic signalling pathways 
are under development, and strategies based on targeting intracellular pathways active in 
CSCs, such as Wnt, Bmi-1, Hh, Twist, and Notch, have all been currently considered for 
therapeutic investigation. 
Wnt signalling is a key pathway in cell development and has been shown to be upregulated 
in about 50% of cancers (Deonarain et al., 2009). Inhibition of the Wnt/ǃ-catenin signalling 
pathway has been shown to be effective at blocking epidermal squamous cell carcinoma 
development, and a new approach to antagonise Wnt signalling involves the stabilisation of 
axin, thereby maintaining the ǃ-catenin destruction complex (Huang et al., 2009). The Bmi-1 
molecule has been demonstrated to have a role in lung tumorigenesis and 
bronchioloalveolar stem cell expansion, and Hh signalling has been shown to be critical for 
normal lung development, lung injury repair, and lung carcinogenesis (Peacock & Watkins, 
2008). Furthermore, another study has shown that the Hh pathway can maintain a tumour 
stem cell compartment in multiple myeloma (Peacock et al., 2007). The development of 
specific Hh inhibitors, such as cyclopamine, is currently underway for breast cancer, and 
clinical trials utilising these chemotherapeutical agents are in the planning stages (Liu et al., 
2006; Kakarala & Wicha, 2008). Similarly, aberrant Notch signalling that has been observed 
in several human cancers, such as human T-cell acute lymphoblastic leukaemia, cervical 
cancer, and breast cancer, suggesting that inhibition of Notch may represent a potential 
effective therapeutic target (Nickoloff et al., 2003). Telomerase inhibition also could be 
another effective anti-cancer therapeutic approach that would target both the proliferating 
CSCs as well as the bulk of the cancer cells (Shay & Wright, 2010). 
The inhibition of the Epithelial-mesenchymal transition (EMT) process through 
transcriptional pathways, such as Snail and Twist, can slow the generation of CSCs with 
metastatic capacity. There has been intense investigation with regard to further therapeutic 
strategies based on blocking molecules at the cell surface that are implicated in invasion, 
migration and metastasis, such as integrins, CXCR-4, and CD44. In basal-like breast cancer, 
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the inhibition of Wnt signalling was shown to block stem cell self-renewal and also to 
repress the expression of the CDH1 repressors Slug and Twist, which in turn, block 
metastasis dissemination. In ovarian tumours, it was observed that CD44+ cells expressing 
markers of pluripotent stem cells might have a selective advantage for dissemination 
through their adherence to the hyaluronic acid pericellular coat of adjacent mesothelial cells 
(Bourguignon et al., 2008). 
As therapeutic resistance of CSCs can often be directly attributed to the activity of ALDH or 
ABC surface transporters, additional approaches based on targeting these molecules might 
sensitise CSCs to current standard adjuvant therapies. In addition, given that several types 
of cancer cells have a specific microRNA (miRNA) expression profile, the manipulation of 
mRNA expression levels through miRNAs is another promising strategy by which to target 
CSCs (Alison et al., 2010). 
The stem cell status of the cells of certain cancers can be dynamically regulated by the 
tumour microenvironment. Like normal stem cells, CSCs depend on support from the 
vascular and stromal niche for survival. As the microenvironment adjacent to the blood 
vessels can serve as the local CSC niche, another interesting alternative that is being 
addressed is the targeting of the vasculature, and this strategy could destroy the niche as 
well as the tumour bulk (Calabrese et al., 2007). 
Throughout cancer evolution, it is likely that the genetic instability initiated by several 
selection pressures, such as hypoxia, immune or nutritional status, may result in the 
selection of new phenotypically malignant clones with increased genetic and epigenetic 
alterations. These malignantly transformed cells can acquire a selective growth advantage 
over their normal cell neighbours through resistance to apoptosis or higher proliferation 
rates, and subsequently, a specific clone of cells will develop. Increasingly, additional 
tumour progression with mutations and clonal expansion may give rise to more abnormal 
clones.  In this manner, the more advanced tumours exhibit a complex heterogeneous 
picture, whereas early tumours may be more homogeneous because they did not have 
appropriate time to develop this clonal diversity. The existence of these clones can then 
eventually compromise a targeted therapy against a specific CSC clone because some of the 
cells would tend to expand due to a mutation for selective growth or survival superiority 
(Alison et al., 2011). This is an important problem that must be addressed when designing 
therapies against CSCs. 
The correct identification and targeting of signalling mechanisms that are specific for CSCs 
could provide an opportunity for selective targeting of these cells. In fact, there is currently a 
need for the development of highly specific therapies that target CSCs. Later, these therapies 
will need to be tested in the appropriate oncological patient population, along with the use of 
adequate pharmacodynamic markers. However, the use of combined targeting of different 
CSC pathways, together with the commonly used radio- and chemotherapy applications and 
other types of targeted therapies, remains to be further explored in cancer therapy.  
3.8 The influence of CSCs on tumour prognosis 
If CSCs are associated with carcinogenesis, it follows that their frequency in primary 
tumours correlates with the extent of tumour invasion and dissemination and consequently, 
with patient prognosis. Generally, it is believed that elevated stemness characteristics and a 
high proportion of CSCs in tumours are associated with a worse prognosis.  
Tumoural recurrence, metastasis and survival might be determined by the behaviour of the 
more resistant CSC population. In most cases, patients with tumours expressing high levels 
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of molecules associated with CSCs have a poorer clinical outcome than patients with 
tumours that express low levels of thee molecules. In breast cancer, a high prevalence of 
CSCs was associated with higher biological and molecular heterogeneity, as well as with 
less differentiated tumours (Pece et al., 2010).  
In brain tumours, the ability of tumour cells to propagate neurospheres in culture and high 
CD133 expression on these cells are regarded as independent prognostic factors that are 
being considered by some studies as relevant parameters associated with a reduced time of 
disease-free survival and overall survival. In human pancreatic cancer, in which 60% of 
tumours are CD133+, the CD133+ CSCs that simultaneously displayed CXCR4 expression 
were directly involved in the occurrence of metastasis after orthotopic xenografting, and 
remarkably, these metastases could be blocked by a small molecule inhibitor of CXCR4 
(AMD3100) (Hermann et al., 2007).      
Elevated ALDH expression is also associated with a poor prognosis in several tumour types, 
including AML, prostate cancer, breast cancer, head and neck squamous cell carcinoma, and 
pancreatic cancer (Charafe-Jauffret et al., 2010; Ginestier et al., 2007; Rasheed et al., 2010). 
Similarly, high activity levels of the ABC transporters have also been reported to be a sign of 
poor prognosis in patients with AML (Guo et al., 2009).  
Thus, fundamentally, patients with tumours expressing high levels of the molecules 
associated with CSCs tend to have a poorer clinical outcome than patients with tumours that 
express low levels of these markers. 
4. The prognostic influence of cancer stem cell immunophenotypes in oral 
squamous cell carcinomas 
We recently investigated the presence of CSC antigens by immunostaining to identify a 
putative CSC immunophenotype in oral squamous cell carcinoma (OSCC) and to determine 
its influence on prognosis (Oliveira et al., 2011).  
The initial demonstration that the tumoural cells of head and neck carcinomas have a 
hierarchy of development and embody a subpopulation of cells with self-renewal and 
differentiation capacities was reported by Prince et al. (2007), who found CSCs in low 
percentages and were able to characterise them through CD44 immunoexpression. 
However, to our knowledge, our study was the first to verify the association between 
prognostic factors in OSCC and conventional CSC immunophenotype markers.  
The CD44 proteins are commonly found in epithelial tissues and were previously 
established as fundamental regulatory factors in squamous epithelium for processes such as 
cellular adhesion, cell-cell interaction, infiltration and metastatic dissemination (Bajorath, 
2000). Our findings regarding CD44 immunoexpression in OSCC showed that CD44+ 
tumour cells occurred at a frequency of 41.4% and were associated with basal cell 
morphology. Moreover, our results demonstrated that the overall survival curves presented 
significant differences between CD44+ or CD44- immunophenotypes, as configured by an 
independent factor of poor prognosis in multivariate analysis (hazard ratio, 0.316 [95% 
confidence interval, 0.070–0.664]; P = 0.033).  
These results were consistent with other prognostic studies, suggesting that alterations in 
adhesion molecules can act as either positive or negative regulators of progression and 
metastasis in OSCC, depending on stage when tumour is diagnosed (Wang et al., 2007; 
Wang et al., 2009). In agreement, Bankfalvi et al. (2002) also found that the high 
immunoexpression of CD44 (specifically the CD44v9 alternative splice isoform) was 
significantly associated with a poorer clinical outcome in OSCC. 
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Nevertheless, the effect of CD44 immunoexpression on OSCC prognosis still shows 
discordant results, and there are several candidate stem cell markers that need to be 
assessed. A trustworthy immunophenotypical marker that can be used to isolate the CSCs 
has yet not been definitively established in head and neck cancers, and the identification of 
reliable markers required to characterise CSCs in OSCC could certify the clinical 
effectiveness of future targeted therapies, possibly resulting in a more effective outcome for 
the patients. 
5. Final considerations 
There are still many aspects that remain to be discovered in the field of CSCs. Although 
there is much to be learned about the mechanisms that regulate normal stem cell function 
and how they can be used by malignant cells to propagate the disease, the careful 
identification of the main differences between normal adult stem cells and CSCs, as well as 
of their overlapping aspects, are important to discern how cancers progress and to 
transform the advances in CSC biology into effective therapies that could help patients in 
the near future. Therefore, the interaction between the expression of CSC markers and 
malignant behaviour need to be adequately understood as they relate to prognostic factors 
in several cancer types. 
We believe that most human solid and haematological cancers contain a subpopulation of 
CSCs. Experimental and clinical evidence sustain the hypothesis that in humans, the process 
of tumorigenesis initiates in an adult normal stem cell, although other more committed cells, 
particularly in the haematopoietic system, might also be the founder cells of malignancy. 
Several therapeutic approaches have been shown to be promising by targeting CSCs in 
tumours, which is a great challenge given that these cells seem to be specifically resistant to 
currently available therapies. 
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cells that both disseminate cancers and defy oncotoxic drugs and radiation directed at rapidly dividing bulk
cancer cells, but research on cancer stem cells has paid dividends for cancer prevention, detection, targeted
treatment, and improved prognosis.
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